Lingmin Yang 1,2 , Ranliang Cui 3 , Yueguo Li 3 , Kai Liang 4 , Min Ni 5 , Yajun Gu 1 Show Affiliations »
Abstract
OBJECTIVE: To explore novel biomarkers for patients with pancreatic ductal adenocarcinoma (PDAC), from the perspective of tumor hypoxia. METHODS: We screened 29 differentially expressed and hypoxia-upregulated genes from the Oncomine database. A total of 12 secretory proteins that interact with hypoxia-inducible factor 1 (HIF-1A) were selected by STRING (protein-protein interaction networks). After excluding enzymes and collagens, insulin-like growth factor-binding protein 3 (IGFBP3), glycoprotein NBM (GPNMB), transforming growth factor-β-induced (TGFBI), and biglycan (BGN) were detected by sandwich enzyme-linked immunosorbent assay (ELISA) in patients with cancer and healthy control individuals. RESULTS: The serum level of TGFBI was significantly elevated in patients with PDAC, compared with healthy controls; the assay could discriminate among cases of PDAC in different clinical stages. The amount of TGFBI was significantly decreased after treatment. The combination of TGFBI and cancer antigen (CA) 19-9 was more accurate than TGFBI or CA 19-9 alone as diagnostic markers. Also, TGFBI might be used as a prognostic marker according to the PROGgeneV2 Pan Cancer Prognostics Database. CONCLUSIONS: Serum TGFBI, combined with CA 19-9, offers higher diagnostic value than other methods for patients with PDAC. Also, TGFBI might be used as a prognostic marker. © American Society for Clinical Pathology 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
OBJECTIVE: To explore novel biomarkers for patients with pancreatic ductal adenocarcinoma (PDAC ), from the perspective of tumor hypoxia . METHODS: We screened 29 differentially expressed and hypoxia -upregulated genes from the Oncomine database. A total of 12 secretory proteins that interact with hypoxia -inducible factor 1 (HIF-1A ) were selected by STRING (protein-protein interaction networks). After excluding enzymes and collagens, insulin-like growth factor-binding protein 3 (IGFBP3 ), glycoprotein NBM (GPNMB ), transforming growth factor-β-induced (TGFBI ), and biglycan (BGN ) were detected by sandwich enzyme-linked immunosorbent assay (ELISA) in patients with cancer and healthy control individuals. RESULTS: The serum level of TGFBI was significantly elevated in patients with PDAC , compared with healthy controls; the assay could discriminate among cases of PDAC in different clinical stages. The amount of TGFBI was significantly decreased after treatment. The combination of TGFBI and cancer antigen (CA) 19-9 was more accurate than TGFBI or CA 19-9 alone as diagnostic markers. Also, TGFBI might be used as a prognostic marker according to the PROGgeneV2 Pan Cancer Prognostics Database. CONCLUSIONS: Serum TGFBI , combined with CA 19-9, offers higher diagnostic value than other methods for patients with PDAC . Also, TGFBI might be used as a prognostic marker. © American Society for Clinical Pathology 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Entities: Disease
Gene
Species
Keywords:
CA 19-9; HIF-1A; TGFBI; biomarker; hypoxia; pancreatic ductal adenocarcinoma
Mesh： See more »
Substances： See more »
Year: 2020
PMID： 31626700 DOI： 10.1093/labmed/lmz063
Source DB: PubMed Journal: Lab Med ISSN： 0007-5027